Used in cancer research and therapy development, particularly targeting tumor angiogenesis. It inhibits DLL4 (Delta-like ligand 4), a key protein in the Notch signaling pathway, which plays a critical role in blood vessel formation within tumors. By blocking DLL4, it disrupts the development of new blood vessels that supply nutrients to cancer cells, leading to reduced tumor growth and metastasis. Investigated in preclinical and clinical studies for various solid tumors, including lung, pancreatic, and ovarian cancers. Often used as a reference standard in antibody development and comparative studies due to its well-characterized mechanism and high specificity.